TP53 and B-cell chronic lymphocytic leukemia: Recent studies have illustrated the development of 17p and 11q deletions during the disease course, and associated clonal evolution of new 17p deletions with the presence of foregoing therapy.13, 14 Concerning TP53 mutations, well-documented cases of their acquirement under the pressure of chemotherapy have also been reported by us and independently by others.15, 16, 17, 18 This led to the suggestion that TP53 mutations should be investigated before each therapy in CLL patients.19